Resveratrol in Periodontitis Treatment: Efficacy and Mechanism of Action in Rat Models and its Clinical Implications

Abstract

Periodontitis, a prevalent periodontal disease, serves as the foundation for numerous periodontal pathologies. The current study aimed to examine the adjunctive role of resveratrol in treating periodontitis. Our findings reveal that resveratrol significantly augments periodontal health of patients, indicating its substantial efficacy. Further experimentation involving the construction of a rat model of periodontitis demonstrated that resveratrol effectively mitigates periodontal tissue damage and inhibits apoptosis in periodontal cells. This confirms resveratrol's promising clinical applicability. Moreover, the Osteoclastogenesis inhibitory factor/Recombinant receptor activator of nuclear factor kappa B/Recombinant receptor activator of nuclear factor kappa B-Ligand pathway is pivotal in modulating the pathological progression of periodontitis. This pathway exhibited significant activation in rats afflicted with periodontitis, and resveratrol intervention effectively regulated its expression. These findings suggest that the therapeutic impact of resveratrol on periodontitis could be attributed to the inhibition of the Osteoclastogenesis inhibitory factor/Recombinant receptor activator of nuclear factor kappa B/Recombinant receptor activator of nuclear factor kappa B-Ligand pathway.